Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Foundation Medicine and AstraZeneca Announce Genomic Profiling Collaboration

Published: Monday, November 12, 2012
Last Updated: Monday, November 12, 2012
Bookmark and Share
Collaboration seeks to enhance clinical trial design by identifying genomic predictors of response to targeted cancer therapies.

Foundation Medicine, Inc. announced a multi-year collaboration with AstraZeneca to identify alterations found in cancer-related tumor genes that may predict a person’s response or resistance to targeted medicines. Working with Foundation Medicine to reveal these genomic alterations may help AstraZeneca to research new medicines for people with cancer. Under the terms of the collaboration, Foundation Medicine was also granted right of first negotiation for the development of potential diagnostic products.
Susan Galbraith, Vice President and Head of the AstraZeneca Oncology Innovative Medicines Unit said, “Our scientific understanding of cancer and the pathways driving tumour growth enables us to focus on which people are most likely to respond to our medicines. This collaboration with Foundation Medicine will help us to identify tumour-specific defects and alterations that can be used for patient segmentation.”

“AstraZeneca has a strong commitment to understanding the patient-to-patient variations that may impact the efficacy of therapeutic candidates,” said Michael J. Pellini, M.D., president and chief executive officer, Foundation Medicine. “We are helping companies like AstraZeneca achieve deeper insight into their programs and trials with our unique cancer expertise and our ability to provide genomic information that can impact clinical treatment decisions. Together, we expect to enable a more individualized, targeted approach to cancer drug development and clinical trials.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Foundation Medicine, AstraZeneca Collaborate
Foundation Medicine has announced an agreement with AstraZeneca to develop companion diagnostic assays to facilitate personalized medicine in oncology by identifying patients most likely to benefit from medicines within AstraZeneca's oncology pipeline.
Thursday, May 05, 2016
Foundation Medicine, IMS Health Collaborate
IMS Health will combine its Real-World Evidence platform with Foundation Medicine's FoundationCore knowledge base, enabling clients to interpret real-world oncology outcomes, the firms said today.
Tuesday, June 23, 2015
Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration
Collaboration to address needs of biopharmaceutical companies conducting clinical R&D in China.
Friday, October 31, 2014
Foundation Medicine Extends and Expands Collaboration with Novartis
Collaboration will now extend through at least September 2016.
Wednesday, January 08, 2014
Foundation Medicine and Memorial Sloan-Kettering Cancer Center Announce Partnership
Partners will co-develop a genomic test to help guide treatment decisions for patients diagnosed with leukemia, lymphoma or myeloma.
Friday, May 03, 2013
Foundation Medicine Announces $42.5 Million Series B Financing
Syndicate includes leading public and strategic investors; proceeds will expand commercial operations and accelerate adoption of FoundationOne™.
Monday, October 01, 2012
Foundation Medicine Enters Extensive Collaboration with Novartis
Pilot agreement extended to a broad financial commitment over three years.
Monday, June 11, 2012
Foundation Medicine’s Next-Generation Sequencing Data to be Presented at 103rd AACR Annual Meeting 2012
Genomic profile demonstrates high concordance with existing commercial assays and identifies broader range of actionable alterations.
Wednesday, March 28, 2012
Foundation Medicine and Dana-Farber Cancer Institute Identify Novel Genomic Alterations in Lung and Colorectal Cancer
Findings highlight clinical application of next-generation sequencing to suggest targeted therapeutic options for patients.
Tuesday, February 14, 2012
Foundation Medicine Receives CLIA Certification for Its Genomic Sequencing Laboratory
This certification follows receipt of a Massachusetts State license and allows the company to accept clinical samples from most U.S. states.
Friday, February 03, 2012
Foundation Medicine Announces Collaboration with Sanofi
Fifth partnership will help translate cancer genomic science to clinical results. Foundation Medicine will use their genomic sequencing and analytic capabilities to identify genetic biomarkers and potential companion diagnostics for select Sanofi oncology drug candidates.
Friday, January 13, 2012
Foundation Medicine Appoints Molecular Diagnostics Industry Leader Maureen T. Cronin, Ph.D., as Senior Vice President of Research and Product Development
Foundation Medicine, Inc., a personalized cancer medicine company that aims to bring comprehensive cancer genome analysis to routine clinical care, have announced the appointment of Maureen T. Cronin, Ph.D., to the newly created position of senior vice president, research and product development.
Tuesday, November 16, 2010
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!